AD patients can undergo CSF collection to test for amyloid β‐protein (Aβ) 42 or the Aβ42/40 ratio, as well as phospho‐Tau (p‐Tau) levels, or receive amyloid and Tau PET scans. This evidence concerns the gene MAPT and Alzheimer disease.